Uptown Research Institute

Chicago, Illinois 60640

9 studies enrolling now · 40 studies all time

What they study most

Alzheimer Disease, Antipsychotic Agents, Binge Eating Disorder, Bipolar Disorder, Central Nervous System Depression, Central Nervous System Diseases, Cognition, Cognitive Impairment Associated With Schizophrenia (CIAS), Generalized Anxiety Disorder, Major Depressive Disorder, Mental Disorders, Molecular Mechanisms of Pharmacological Action

Studies at this site

• A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Recruiting now
• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia — Recruiting now
• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia — Recruiting now
• "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Recruiting now
• RE104 Safety and Efficacy Study in Generalized Anxiety Disorder — Recruiting now
• A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia — Recruiting now
• An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1) — Recruiting now
• A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT — Recruiting now
• A Study to Evaluate the Effect of KarXT on Urological Safety — Recruiting now
• Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) — Enrolling by invitation
• A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) — Running, not enrolling
• Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) — Completed
• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder — Completed
• Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression — Completed
• BHV-7000 Open-Label Extension Bipolar Mania Study — Stopped early
• BHV-7000 Acute Treatment of Bipolar Mania — Completed
• A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) — Running, not enrolling
• Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia — Completed
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) — Completed
• A Study of Paliperidone Palmitate 6-Month Formulation — Completed
• Safety and Efficacy of HB-1 for Panic Disorder — Completed
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) — Completed
• A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication — Completed
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) — Completed
• Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 — Completed
• Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder — Completed
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) — Completed
• This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia — Completed
• A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder — Completed
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® — Stopped early
• Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms — Completed
• SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder — Completed
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia — Completed
• Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients — Completed
• Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia — Completed
• A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. — Completed
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — Completed
• Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia — Completed